Calculate Your Salary Ranking
Home > Arno Therapeutics Salary

Arno Therapeutics Salary
  • 84
  • 39
  • 34

Arno Therapeutics average salary is $-, median salary is $- with a salary range from $- to $-.
Arno Therapeutics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Arno Therapeutics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 0 Arno Therapeutics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Arno Therapeutics Salaries (February 24, 2017)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Arno Therapeutics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Arno Therapeutics Information
  • Arno Therapeutics Inc
  • Industry: BioTech/Drugs
  • City: Parsippany, NJ
  • Arno Therapeutics is a biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients.Arno is initially focusing its efforts on developing its lead compound, AR-67, a novel anti-cancer agent. AR-67 is a third generation campthothecin analogue currently in Phase I clinical trials that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing AR-12 and AR-42, two novel, preclinical oncology products. A key component of the Company's strategy is to acquire global rights to additional product candidates for the treatment of cancer while continuing